DK1069912T3 - Injicerbare IGF-formuleringer, der indeholder succinat som puffermiddel - Google Patents

Injicerbare IGF-formuleringer, der indeholder succinat som puffermiddel

Info

Publication number
DK1069912T3
DK1069912T3 DK99916414T DK99916414T DK1069912T3 DK 1069912 T3 DK1069912 T3 DK 1069912T3 DK 99916414 T DK99916414 T DK 99916414T DK 99916414 T DK99916414 T DK 99916414T DK 1069912 T3 DK1069912 T3 DK 1069912T3
Authority
DK
Denmark
Prior art keywords
igf
injectable
buffer
formulations containing
formulations
Prior art date
Application number
DK99916414T
Other languages
English (en)
Inventor
Bret Shirley
Maninder S Hora
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of DK1069912T3 publication Critical patent/DK1069912T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
DK99916414T 1998-04-03 1999-04-02 Injicerbare IGF-formuleringer, der indeholder succinat som puffermiddel DK1069912T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8000898P 1998-04-03 1998-04-03
PCT/US1999/007531 WO1999051272A1 (en) 1998-04-03 1999-04-02 Injectable igf-formulations containing succinate as buffering agent

Publications (1)

Publication Number Publication Date
DK1069912T3 true DK1069912T3 (da) 2007-11-12

Family

ID=22154445

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99916414T DK1069912T3 (da) 1998-04-03 1999-04-02 Injicerbare IGF-formuleringer, der indeholder succinat som puffermiddel

Country Status (10)

Country Link
US (1) US20070249522A1 (da)
EP (1) EP1069912B1 (da)
JP (1) JP2002510653A (da)
AT (1) ATE367828T1 (da)
AU (1) AU3473999A (da)
DE (1) DE69936638T2 (da)
DK (1) DK1069912T3 (da)
ES (1) ES2288018T3 (da)
PT (1) PT1069912E (da)
WO (1) WO1999051272A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203133A3 (en) 1999-10-04 2005-07-28 Chiron Corp Emeryville Stabilized liquid polypeptide-containing pharmaceutical compositions
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2003018782A2 (en) 2001-08-30 2003-03-06 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
WO2003024472A2 (en) 2001-09-14 2003-03-27 Stem Cell Therapeutics Inc. Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
AU2002325710A1 (en) * 2001-09-18 2003-04-01 Stem Cell Therapeutics Inc. Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
AU2003250705A1 (en) 2002-07-31 2004-02-16 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
EP2174663A1 (en) 2003-01-08 2010-04-14 Novartis Vaccines and Diagnostics, Inc. Stabilized aqueous compositions comprising tissue factor pathway inhibitor (TFPI) or tissue factor pathway inhibitor variant
CA2664629A1 (en) 2005-09-27 2007-04-05 Christopher Gregg Oligodendrocyte precursor cell proliferation regulated by prolactin
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
US11097023B1 (en) * 2020-07-02 2021-08-24 Par Pharmaceutical, Inc. Pre-filled syringe containing sugammadex

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0080879B1 (en) * 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
JPS6069037A (ja) * 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
ATE90570T1 (de) * 1988-01-29 1993-07-15 Sumitomo Pharma Verbesserte formulierungen mit kontrollierter abgabe.
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
JP3698721B2 (ja) * 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド 有機溶媒を用いて処理したポリペプチドの賦形剤安定化
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US6511811B1 (en) * 1995-06-07 2003-01-28 The Regents Of The University Of California Protein kinase C antagonist related to insulin receptor
US5977057A (en) * 1996-05-08 1999-11-02 The University Of Vermont And State Agricultural College Thrombosis prophylaxis for factor VLEIDEN carriers
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
GB2326279B (en) * 1997-06-11 2002-07-31 Hyundai Electronics Ind Method of forming a capacitor of a semiconductor device
US6663899B2 (en) * 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta

Also Published As

Publication number Publication date
DE69936638D1 (de) 2007-09-06
EP1069912B1 (en) 2007-07-25
ES2288018T3 (es) 2007-12-16
WO1999051272A1 (en) 1999-10-14
AU3473999A (en) 1999-10-25
PT1069912E (pt) 2007-09-14
DE69936638T2 (de) 2008-05-21
EP1069912A1 (en) 2001-01-24
JP2002510653A (ja) 2002-04-09
US20070249522A1 (en) 2007-10-25
ATE367828T1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
CO5090908A1 (es) Procedimiento para administrar peptidos insulinotropicos
TWI262925B (en) GLP-1 analogues
AU7315301A (en) Compounds and compositions for delivering active agents
IL140930A0 (en) Compounds and compositions for delivering active agents
ATE270898T1 (de) Stabile igf/igfbp pharmazeutische formulierungen
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
HUP0004447A2 (hu) Stabilizált teriparatid oldatok
IL140710A0 (en) Pulmonary delivery of active agents
DK1069912T3 (da) Injicerbare IGF-formuleringer, der indeholder succinat som puffermiddel
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
RS105704A (sr) Kiseli preparati insulina sa poboljšanom stabilnošću
DE69922043D1 (de) Glp-1 analoge
AR021370A1 (es) Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides
MX9202328A (es) Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo.
MY128850A (en) Non-aqueous polar aprotic peptide formulations
MY121684A (en) Non-aqueous protic peptide formulations
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
NO20045507L (no) Injiserbare faste hyaluronsyrebaerere for levering av osteogene proteiner
RS50046B (sr) Farmaceutske kompozicije tizoksanida i nitazoksanida
AU4419497A (en) Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
MX9301387A (es) Metodo y composicion para el tratamiento de osteoporosis.
ES2174838T3 (es) Metodo para aumentar la absorcion del intestino.
AR020106A1 (es) Variantes estabilizadas del inhibidor de la subtilisina de streptomyces, gen mutante que la codifica y composicion que comprende dicha variante
MXPA05010390A (es) Composiciones y metodos para la liberacion de timosina beta 4, analogos, isoformas y otros derivados.